Table 3.
The incidence of clinical serious adverse events of CAR-T in solid tumors.
| NCT Number | Conditions | Interventions | Characteristics | Country | Adverse event assessment criteria | Enrollment/n | All-Cause Mortality(n/Total) | Serious adverse events(n/Total) | Other (Not Including Serious) Adverse Events(n/Total) |
|---|---|---|---|---|---|---|---|---|---|
| NCT02664363 | Glioblastoma;Gliosarcoma | EGFRvIII CAR-T cells | Phase 1 | United States | CTCAE v5.0 | 3 | 3/3 | 1/3 | 3/3 |
| NCT03330834 | Advanced Lung Cancer | PD-L1 CAR-T cells | Phase 1 | China | CTCAE v4.0 | 1 | 1/1 | 1/1 | 1/1 |
| NCT01454596 | Malignant Glioma; Glioblastoma; Brain Cancer; Gliosarcoma |
EGFRvIII CAR-T cells | Phase 1 Phase 2 |
United States | CTCAE v4.0 | 18 | 1/18 | 2/18 | 18/18 |
| NCT01583686 | Cervical Cancer; Pancreatic Cancer; Ovarian Cancer; Mesothelioma;Lung Cancer |
Anti-mesothelin CAR-T cells | Phase 1 Phase 2 |
United States | CTCAE v4.0 | 15 | 1/15 | 5/15 | 15/15 |
| NCT01218867 | Metastatic Cancer; Metastatic Melanoma; Renal Cancer |
Anti-VEGFR2 CAR-T cells |
Phase 1 Phase 2 |
United States | CTCAE v3.0 | 22 | 1/22 | 5/22 | 21/22 |
| NCT02761915 | Relapsed or Refractory Neuroblastoma |
Genetic/1RG-CAR-T cells | Phase 1 | United Kingdom | CTCAE v4.0 | 12 | 6/12 | 5/12 | 12/12 |
| NCT02706392 | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Recurrent Acute Lymphoblastic Leukemia; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia |
ROR1 CAR-T cells | Phase 1 | United States | CTCAE v4.0 | 21 | 12/21 | 17/21 | 21/21 |
All clinicaltrials can be downloaded from www.clinicaltrials.gov (accessed October 02, 2022).